SCHEMBL29540332

SCHEMBL29540332

NC(=O)c1ccc2ccccc2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.68
ALDH1A1 P00352 3/20 0.65
MAPT P10636 2/20 0.65
GAA P10253 1/20 0.65
CNR2 P34972 5/20 0.61
HDAC8 Q9BY41 1/20 0.61
KDM4E B2RXH2 3/20 0.56
NFKB1 P19838 2/20 0.56
RAB9A P51151 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
PIM1 P11309 1/20 0.55
KDM4C Q9H3R0 1/20 0.53
TSHR P16473 2/20 0.51
MEN1 O00255 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.50
IKBKB O14920 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL367913 1.00 MGAM (0.68) MGAMALDH1A1MAPTGAACNR2
SCHEMBL5788458 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL29135887 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Hydrochloric Acid SCHEMBL3401098 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL5788456 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Ammonia Solution, Strong SCHEMBL29239526 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL31434313 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Hydrochloric Acid SCHEMBL3400880 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Thiophene SCHEMBL3425727 0.89 MGAM (0.56) MGAMALDH1A1MAPTGAACNR2
Phthalic Acid SCHEMBL30909153 0.89 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119462501-A Preparation method of 2-quinolinamide compound promoted by acidic ionic liquid 内蒙古民族大学 2025-02-18 CN claimed
US-20230133600-A1 PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2023-05-04 US claimed
EP-4098258-A1 PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2022-12-07 EP claimed
US-20220112177-A1 KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF FUDAN UNIVERSITY (CN) 2022-04-14 US claimed
US-12636275-B2 Pharmaceutical use of ketoamide-based compound SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2026-05-26 US disclosed
EP-4720043-A1 SOLID FORM OF A QUINOLINE CARBOXAMIDE COMPOUND Syngenta Crop Protection AG (CH) 2026-04-08 EP disclosed
EP-4720043-A1 SOLID FORM OF A QUINOLINE CARBOXAMIDE COMPOUND Syngenta Crop Protection AG (CH) 2026-04-08 EP disclosed
WO-2026047037-A1 MICROBIOCIDAL QUINOLINE-AMIDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2026-03-05 WO disclosed
WO-2026047037-A1 MICROBIOCIDAL QUINOLINE-AMIDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2026-03-05 WO disclosed
WO-2026008511-A1 MICROBIOCIDAL QUINOLINE-AMIDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2026-01-08 WO disclosed
WO-2025247781-A1 SOLID FORM OF A QUINOLINE CARBOXAMIDE COMPOUND SYNGENTA CROP PROTECTION AG (CH) 2025-12-04 WO disclosed
WO-2025247782-A1 SOLID FORM OF A QUINOLINE CARBOXAMIDE COMPOUND SYNGENTA CROP PROTECTION AG (CH) 2025-12-04 WO disclosed
US-20220218693-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE KABUSHIKI KAISHA YAKULT HONSHA (JP) 2022-07-14 US disclosed
US-20220218693-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE KABUSHIKI KAISHA YAKULT HONSHA (JP) 2022-07-14 US disclosed
EP-3854397-A4 CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE Kabushiki Kaisha Yakult Honsha (JP) 2022-07-13 EP disclosed
CN-112239425-B Preparation method of aporphine alkaloid and intermediate thereof 温州医科大学 2022-06-21 CN disclosed
CN-112239424-B Preparation method of aristolochia alkaloids and intermediate thereof 温州医科大学 2022-06-21 CN disclosed
US-20220169640-A1 PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF KABUSHIKI KAISHA YAKULT HONSHA (JP) 2022-06-02 US disclosed
US-20220112177-A1 KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF FUDAN UNIVERSITY (CN) 2022-04-14 US disclosed
EP-3960199-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE Kabushiki Kaisha Yakult Honsha (JP) 2022-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112177-A1 KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF ACE, REN, ACE2 MGAM 134/4885ALDH1A1 1463/4885MAPT 766/4885
US-20230133600-A1 PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND CTSL, CTSV, CTSS MGAM 75/4885ALDH1A1 2113/4885MAPT 2343/4885
US-20220169640-A1 PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF BCKDK, CBR3, NQO2 MGAM 1079/4885ALDH1A1 213/4885MAPT 3851/4885
US-12636275-B2 Pharmaceutical use of ketoamide-based compound CTSV, CTSL, CTSS MGAM 616/4885ALDH1A1 2589/4885MAPT 4005/4885
US-20220218693-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE STAT3, PDCD1, CD274 MGAM 3443/4885ALDH1A1 742/4885MAPT 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.